Acrodermatitis chronica atrophicans historical perspective: Difference between revisions
No edit summary |
|||
Line 2: | Line 2: | ||
{{CMG}}; {{AE}} {{RT}} | {{CMG}}; {{AE}} {{RT}} | ||
{{ACA}} | {{ACA}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==Overview== | ==Overview== |
Revision as of 19:39, 19 December 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Acrodermatitis chronica atrophicans Microchapters |
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acrodermatitis chronica atrophicans historical perspective On the Web |
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans historical perspective |
FDA on Acrodermatitis chronica atrophicans historical perspective |
CDC on Acrodermatitis chronica atrophicans historical perspective |
Acrodermatitis chronica atrophicans historical perspective in the news |
Blogs on Acrodermatitis chronica atrophicans historical perspective |
Risk calculators and risk factors for Acrodermatitis chronica atrophicans historical perspective |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it. Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.